Utveckla en EIC Accelerator-ansökan avseende Celluminovas banbrytande detektering av gliomstamceller

Purpose and goal

Celluminova is developing a drug, GlioStem, for the detection and visualization of glioma stem cells during surgery of glioma patients to increase maximum safe tumor resection. The aim of the project is to develop a competitive EIC Accelerator application and to prepare a convincing project presentation for the interview phase. The goal is to obtain funding to conduct a First-in-Human clinical study and Phase II clinical study to demonstrate GlioStem´s safety, tolerability and usability.

Expected effects and result

The project should result in a competitive proposal to EIC Accelerator with the goal of our proposal being approved. A grant from EIC Accelerator would take Celluminova through phase I (First-in-human) and phase II clinical studies and thus a big step closer to market approval of GlioStem. This would also significantly strengthen the company´s value and provide an advantageous position before market negotiations.

Planned approach and implementation

To develop a highly competitive proposal that complies with the proposal requirements and is benchmarked against the evaluation criteria. To do this, we will develop an R&D plan with realistic timelines and key milestones. We will also define a commercialisation strategy and perform a competition analysis. Potential project partners will be identified and contacted. Finally, we will create a video pitch and a pitch deck to present the company and our drug candidate.